{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:39:03Z","timestamp":1787107143859,"version":"build-2736575974"},"reference-count":22,"publisher":"Scientific Scholar","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      Biochemical recurrence (BCR) after initial management of Prostate Carcinoma (PC) is frequent. Subsequent interventions rely on disease burden and metastasis distribution.\n                      <jats:sup>68<\/jats:sup>\n                      Ga prostate-specific membrane antigen positron emission tomography\/computed tomography (PSMA PET\/CT) is an excellent imaging modality in BCR. However,\n                      <jats:sup>68<\/jats:sup>\n                      Ga is radionuclide generator produced and has restricted availability.\n                      <jats:sup>99<\/jats:sup>\n                      mTc-labeled PSMA could be a potential cost-effective alternative. We compared the performance of\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-PSMA single-photon emission CT (SPECT)\/CT and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA PET\/CT in BCR with a serum prostate surface antigen (PSA) level of &lt;20 ng\/mL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      The prospective study included 25 patients with BCR and at least one lesion on a\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA PET\/CT. All patients underwent 99 mTc-PSMA SPECT\/CT, and disease distribution and metastatic burden were compared with\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA PET\/CT. The maximum standard uptake value (SUVmax) and the tumor-to-background ratio (TBR) were computed and analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean age and serum PSA (SPSA) were 69.72 \u00b1 6.69 years and 5.65 \u00b1 6.07 ng\/mL. Eleven patients (44%) had SPSA \u22642 ng\/mL. Recurrent sites were noted in the prostate (19, 76%), prostatic bed (3, 12%), and pelvis lymph nodes (LNs) (13, 52%). Distant metastasis to bones (13, 52%), lungs (5, 20%), and retroperitoneal LNs (2, 8%) were noted. Both modalities were concordant for the recurrent disease at the prostate, prostatic bed, bone, and lung lesions.\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-PSMA could localize pelvis LNs in most patients (10\/13, 76.9%). The site-specific sensitivity and specificity between the two modalities were not significantly different (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05). TBR shows excellent correlation with SUVmax (0.783,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Four (16%) patients were understaged with\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-PSMA due to the nonvisualization of the subcentimeter size LNs. No patient with systemic metastases was understaged.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-PSMA SPECT\/CT has good concordance with\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA PET\/CT in BCR, even at low PSA levels. However, it may miss a few subcentimeter LNs due to lower resolution.\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-PSMA SPECT\/CT could be a simple, cost-effective, and readily available imaging alternative to PET\/CT.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijnm.ijnm_8_24","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T12:00:09Z","timestamp":1723896009000},"page":"170-176","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["An Analysis of the Diagnostic Performance of Tc-99m PSMA SSPECT\/CT in Biochemically Recurrent Prostate Cancer Compared with Ga-68 PSMA PET\/CT: A Single-center, Prospective Study"],"prefix":"10.25259","volume":"39","author":[{"given":"Manish","family":"Ora","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek Kumar","family":"Saini","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Dixit","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday Pratap","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Urology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Gambhir","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"R1-20240902","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R2-20240902","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"R3-20240902","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.juro.2015.12.075","article-title":"Standardizing the definition of biochemical recurrence after radical prostatectomy-what prostate specific antigen cut point best predicts a durable increase and subsequent systemic progression?","volume":"195","author":"Toussi","year":"2016","journal-title":"J Urol"},{"key":"R4-20240902","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000481438","article-title":"Management of biochemical recurrence after primary curative treatment for prostate cancer:A review","volume":"100","author":"Artibani","year":"2018","journal-title":"Urol Int"},{"key":"R5-20240902","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/pcan.2016.71","article-title":"Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer:Post hoc analysis of PREVAIL","volume":"20","author":"Bryce","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R6-20240902","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1148\/rg.2020190121","article-title":"Current imaging techniques for and imaging spectrum of prostate cancer recurrence and metastasis:A pictorial review","volume":"40","author":"Tanaka","year":"2020","journal-title":"Radiographics"},{"key":"R7-20240902","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","article-title":"Prostate-specific membrane antigen expression as a predictor of prostate cancer progression","volume":"38","author":"Perner","year":"2007","journal-title":"Hum Pathol"},{"key":"R8-20240902","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/pros.21241","article-title":"High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer","volume":"71","author":"Minner","year":"2011","journal-title":"Prostate"},{"key":"R9-20240902","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ajur.2020.02.001","article-title":"(68)Ga-PSMA PET\/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy","volume":"8","author":"Yuminaga","year":"2021","journal-title":"Asian J Urol"},{"key":"R10-20240902","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid \u2076\u2078Ga-PSMA Ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"R11-20240902","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","article-title":"Comparing the diagnostic performance of radiotracers in recurrent prostate cancer:A systematic review and network meta-analysis","volume":"48","author":"Alberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20240902","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/ph14080713","article-title":"[(68)Ga] Ga-PSMA-11:The first FDA-approved (68)Ga-radiopharmaceutical for PET imaging of prostate cancer","volume":"14","author":"Hennrich","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"R13-20240902","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2967\/jnumed.116.178939","article-title":"Preclinical evaluation and first patient application of 99mTc-PSMA-I and S for SPECT imaging and radioguided surgery in prostate cancer","volume":"58","author":"Robu","year":"2017","journal-title":"J Nucl Med"},{"key":"R14-20240902","first-page":"1","article-title":"Direct comparison of (99m)Tc-PSMA SPECT\/CT and (68)Ga-PSMA PET\/CT in patients with prostate cancer","volume":"8","author":"Albalooshi","year":"2020","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"R15-20240902","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13550-020-00635-z","article-title":"[(99cm)Tc] Tc-PSMA-I and S-SPECT\/CT:Experience in prostate cancer imaging in an outpatient center","volume":"10","author":"Werner","year":"2020","journal-title":"EJNMMI Res"},{"key":"R16-20240902","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.urology.2006.03.075","article-title":"Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer","volume":"68","author":"Kupelian","year":"2006","journal-title":"Urology"},{"key":"R17-20240902","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","article-title":"Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer:The American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes","volume":"177","author":"Cookson","year":"2007","journal-title":"J Urol"},{"key":"R18-20240902","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer:An autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"R19-20240902","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1590\/s1677-5538.ibju.2019.0817","article-title":"68Ga-prostate-specific membrane antigen (psma) positron emission tomography (pet) in prostate cancer:A systematic review and meta-analysis","volume":"47","author":"Matushita","year":"2021","journal-title":"Int Braz J Urol"},{"key":"R20-20240902","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/pros.23379","article-title":"Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT\/CT in prostate carcinoma:A comparative analysis with Ga-68 PSMA PET\/CT","volume":"77","author":"Lawal","year":"2017","journal-title":"Prostate"},{"key":"R21-20240902","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/pros.23444","article-title":"(99m) Tc-MIP-1404-SPECT\/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer","volume":"78","author":"Schmidkonz","year":"2018","journal-title":"Prostate"},{"key":"R22-20240902","first-page":"332","article-title":"Head to head comparison performance of (99m)Tc-EDDA\/HYNIC-iPSMA SPECT\/CT and (68)Ga-PSMA-11 PET\/CT a prospective study in biochemical recurrence prostate cancer patients","volume":"8","author":"Garc\u00eda P\u00e9rez","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"}],"container-title":["Indian Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijnm.ijnm_8_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:38:11Z","timestamp":1779694691000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijnm.co.in\/an-analysis-of-the-diagnostic-performance-of-tc-99m-psma-sspect-ct-in-biochemically-recurrent-prostate-cancer-compared-with-ga-68-psma-pet-ct-a-single-center-prospective-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijnm.ijnm_8_24","relation":{},"ISSN":["0972-3919","0974-0244"],"issn-type":[{"value":"0972-3919","type":"print"},{"value":"0974-0244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2024-01-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}